NFX

Company

Related News

Portal Biotechnologies Raises $9M, Navikenz Secures $7.5M in Life Sciences AI Funding

Jun 19, 2026

Portal Biotechnologies closes $9M funding round to expand cell engineering platform for drug discovery and cell therapy. Navikenz raises $7.5M seed round to scale AI transformation services focused on life sciences and pharmaceuticals.

Centivax Doses First Participants in Phase 1A Universal Flu Vaccine Trial

Feb 13, 2026

California-based Centivax has begun dosing participants in a Phase 1A clinical trial of Centi-Flu 01, a universal influenza vaccine designed to target conserved viral regions across all flu strains. Initial data from approximately 180 participants is expected within the year.